BRAF and non-Hodgkin lymphoma: 2022), non-Hodgkin lymphoma (NHL) (Xu et al. 2019), and melanoma, are known to display accelerated glucose metabolism. BRAF mutations in melanoma are associated with increased glycolysis. Inhibiting this metabolic pathway can delay the development of resistance to BRAF inhibitors, thereby enhancing therapeutic outcomes in melanoma with BRAF mutations (Brummer et al. 2019).